Email this article A Review on Complications of the Prolonged Use of Proton Pump Inhibitors (PPIs) and Presenting a Case of Barrett’s Esophagus
Abstract
Background: Gastroesophageal reflux disease (GERD) is the most common among gastric disorders and treated by antacids especially proton pump inhibitors (PPIs). Though symptoms are reported to be controlled by PPIs, however the complications like barrettes esophagus, Cancers at GE junction are not studied and reported extensively. In view of symptomatic relief, the long, non-supervised, over the counter medication use has increased. Safety of such long-term has been attempted with the review of available evidence and presentation of a case.
Aim: To update available literature on the long-term use of PPIs and possible mechanisms behind adverse events.
Materials and Methods: A case of Barrette’s esophagus was presented, with long-term use of PPIs. Detailed history taking of the case was done and another evidence synthesis was done on the effects of the long and short-term use of PPIs. The literature search using Medline, Scopus, Scholar on adverse effects of the use of PPIs was done which were language and date unrestricted.
Results: Studies report many adverse effects on short-term (up to 5 years of use, namely: clostridium associated diarrhea, bacterial peritonitis, cholecystitis, pyogenic liver, liver cirrhosis, pneumonia, esophageal inflammations, nocturnal breakthrough acid reflux, interstitial nephritis, drug interaction and nutritional deficiencies mainly of Vitamin B 12 and iron) and long-term use, namely: Concomitant dyspepsia, Barrettes esophagus, osteoporosis, dementia, hypomagnesia, cancers at GE junction.
Conclusion: The health care providers and community should be made cautious, larger cohort observational studies are also recommended for more evidence.
Keywords
Full Text:
PDFReferences
Brands of Pantoprazole. Available from:
h t t p : / / w w w. d r u g s u p d a t e . c o m / b r a n d /
showavailablebrands/99/17. Accessed on: August
, 2018.
Proton Pump Inhibitors Market - Segmented
by Drug and Geography - Growth, Trends, and
Forecast (2018-2023). Available from: https://www.
mordorintelligence.com/industry-reports/protonpump-
inhibitors-market. Accessed on: August 25,
Protonix. Available from: https://www.rxlist.
com/protonix-drug/patient-images-side-effects.
htm#missdose. Accessed on: August 29, 2018.
Leontiadis GI, McIntyre L, Sharma VK et al. Proton
pump inhibitor treatment for acute peptic ulcer
bleeding. Cochrane Database Syst Rev 2004; 3:
CD002094.
Pinto-Sanchez MI, Yuan Y, Bercik P et al. Proton
pump inhibitors for functional dyspepsia. Cochrane
Database Syst Rev. 2017; 3: CD011194.
Van Pinxteren B, Numans ME, Bonis PA et al. Shortterm
treatment with proton pump inhibitors, H2-
receptor antagonists and prokinetics for gastrooesophageal
reflux disease-like symptoms and
endoscopy negative reflux disease. Cochrane
Database Syst Rev. 2001; 4: CD002095.
Leontiadis GI, Sharma VK, Howden CW. Proton pumps
inhibitor therapy for peptic ulcer bleeding in Asia – a
post hoc analysis. Cochrane Collaboration, 2005.
Ito T, Jensen RT. Association of long-term proton
pump inhibitor therapy with bone fractures and
effects on absorption of calcium, vitamin B12, iron,
and magnesium. Curr Gastroenterol Rep 2010; 12(6):
-57.
Desilets AR, Asal NJ, Dunican KC. Considerations for
the use of proton-pump inhibitors in older adults.
Consult Pharm 2012; 27(2): 114-20.
Post market Drug Safety Information for Patients
and Providers. FDA Drug Safety Communication:
Possible increased risk of fractures of the hip, wrist,
and spine with the use of proton pump inhibitors.
USFDA. Retrieved on: 2015-11-03.
Depta JP, Lenzini PA, Lanfear DE et al. Clinical
outcomes associated with proton pump inhibitor
use among clopidogrel-treated patients within
CYP2C19 genotype groups following acute myocardial
infarction. Pharmacogenomics J 2015; 15(1): 20-5.
Aseeri M, Schroeder T, Kramer J et al. Gastric acid
suppression by proton pump inhibitors as a risk
factor for clostridium difficile-associated diarrhea
in hospitalized patients. Am J Gastroenterol 2008;
(9): 2308-13.
Janarthanan S, Ditah I, Adler DG et al. Clostridium
difficile-associated diarrhea and proton pump
inhibitor therapy: a meta-analysis. The American
Journal of Gastroenterology 2012; 107: 1001-10.
Ro Y, Eun CS, Kim HS et al. Risk of Clostridium difficile
infection with the use of a proton pump inhibitor
for stress ulcer prophylaxis in critically Ill patients.
Gut Liver 2016; 10(4): 581-6.
Freedberg DE, Lamousé-Smith ES, Lightdale JR et al.
Use of acid suppression medication is associated with
risk for C. difficile infection in infants and children: a
population-based study. Clin Infect Dis 2015; 61(6):
-7.
Kwok CS, Arthur AK, Anibueze CI, et al. Risk of
clostridium difficile infection with acid suppressing
drugs and antibiotics: meta-analysis. Am J
Gastroenterol 2012; 107(7): 1011-9.
Abraham NS. Proton pump inhibitors: potential
adverse effects. Curr Opin Gastroenterol 2012; 28(6):
-20.
Jackson MA, Goodrich JK, Maxan ME et al. Proton
pump inhibitors alter the composition of the gut
microbiota. Gut 2016; 65(5): 749-56.
Bajaj JS, Ratliff SM, Heuman DM et al. Proton pump
inhibitors are associated with a high rate of serious
infections in veterans with decompensated cirrhosis.
Aliment Pharmacol Ther 2012; 36(9): 866-74.
Huang KW, Kuan YC, Luo JC et al. Impact of long-term
gastric acid suppression on spontaneous bacterial
peritonitis in patients with advanced decompensated
liver cirrhosis. Eur J Intern Med 2016; 32: 91-5.
Lombardo L, Foti M, Ruggia O at al. Increased
incidence of small intestinal bacterial overgrowth
during proton pump inhibitor therapy. Clinical
Gastroenterology and Hepatology 2010; 8(6): 504-8.
García Rodríguez LA, Ruigómez A, Panés J. Use of
acid-suppressing drugs and the risk of bacterial
gastroenteritis. Clin Gastroenterol Hepatol 2007;
(12): 1418-23.
Compare D, Pica L, Rocco A. Effects of long-term PPI
treatment on producing bowel symptoms and SIBO.
Eur J Clin Invest 2011; 41(4): 380-6.
Masclee GM, Coloma PM, Kuipers EJ et al. Increased
risk of microscopic colitis with use of proton pump
inhibitors and non-steroidal anti-inflammatory drugs.
Am J Gastroenterol 2015; 110(5): 749-59.
Chuang SC, Lin CC, Peng CY et al. Proton pump
inhibitors increase the risk of cholecystitis: a
population-based case-control study. Gut 2018.
Wang YP, Liu CJ, Chen TJ et al. Proton pump inhibitor
use significantly increases the risk of cryptogenic
liver abscess: a population-based study. Aliment
Pharmacol Ther 2015; 41(11): 1175-81.
Tsai CF, Chen MH, Wang YP et al. Proton pump
inhibitors increase risk for hepatic encephalopathy
in patients with cirrhosis in a population study.
Gastroenterology 2017; 152(1): 134-41.28. Lin HF, Liao KF, Chang CM et al. Correlation between
proton pump inhibitors and risk of pyogenic liver
abscess. Eur J Clin Pharmacol 2017; 73(8): 1019-25.
Arai N, Nakamizo T, Ihara H et al. Histamine H2-
blocker and proton pump inhibitor use and the
risk of pneumonia in acute stroke: a retrospective
analysis on susceptible patients. PLoS One 2017;
(1): e0169300.
Herzig SJ, Doughty C, Lahoti S et al. Acid-suppressive
medication use in acute stroke and hospital-acquired
pneumonia. Annals of Neurology 2014; 76 (5): 712-8.
Sarkar M, Hennessy S, Yang YX. Proton-pump
inhibitor use and the risk for community-acquired
pneumonia. Ann Intern Med 2008; 149(6): 391-8.
Ho SW, Hsieh MJ, Yang SF et al. Risk of strokeassociated
pneumonia with acid-suppressive drugs: a
population-based cohort study. Medicine (Baltimore)
; 94(29): e1227.
Laheij RJ, Sturkenboom MC, Hassing RJ et al. Risk of
community-acquired pneumonia and use of gastric
acid-suppressive drugs. JAMA 2004; 292(16): 1955-
Kvistholm Jensen A, Simonsen J, Ethelberg S. Use of
proton pump inhibitors and the risk of listeriosis: a
nationwide registry-based case-control study. Clin
Infect Dis 2017; 64(7): 845-51.
Bajaj JS, Ratliff SM, Heuman DM et al. Proton pump
inhibitors are associated with a high rate of serious
infections in veterans with decompensated cirrhosis.
Aliment Pharmacol Ther 2012; 36(9): 866-74.
MacLaren R, Reynolds PM, Allen RR. Histamine-2
receptor antagonists vs proton pump inhibitors on
gastrointestinal tract hemorrhage and infectious
complications in the intensive care unit. JAMA Intern
Med 2014; 174(4): 564-74.
Benson VS, Müllerová H, Vestbo J et al. Associations
between gastro-oesophageal reflux, its management
and exacerbations of chronic obstructive pulmonary
disease. Respir Med 2015; 109(9): 1147-54.
Fass R, Sampliner RE, Malagon IB et al. Failure of
oesophageal acid control in candidates for Barrett’s
oesophagus reversal on a very high dose of proton
pump inhibitor. Aliment Pharmacol Ther 2000; 14(5):
-602.
Ricketson Jeffrey, Kimel Gil, Spence James et al. Acute
allergic interstitial nephritis after use of pantoprazole.
Canadian Medical Association Journal 2009; 180(5):
-8.
Sierra F, Suarez M, Rey M et al. Systematic review:
Proton pump inhibitor-associated acute interstitial
nephritis. Aliment Pharmacol Ther 2007; 26: 545-53.
Antoniou T, Macdonald EM, Hollands S et al. Proton
pump inhibitors and the risk of acute kidney injury
in older patients: A population-based cohort study.
CMAJ Open 2015; 3: E166-71.
Lazarus B, Chen Y, Wilson FP et al. Proton pump
inhibitor use and the risk of chronic kidney disease.
JAMA Intern Med 2016; 176: 238-46.
Xie Y, Bowe B, Li T et al. Proton pump inhibitors and
risk of incident CKD and progression to ESRD. J Am
Soc Nephrol 2016; 27(10): 3153-63.
Wijarnpreecha K, Thongprayoon C, Chesdachai S et
al. Associations of proton-pump inhibitors and H2
receptor antagonists with chronic kidney disease:
a meta-analysis. Dig Dis Sci 2017; 62(10): 2821-7.
Lazarus B, Chen Y, Wilson FP et al. Proton pump
inhibitor use and the risk of chronic kidney disease.
JAMA Intern Med 2016; 176(2): 238-46.
de Francisco ALM, Varas J, Ramos R et al. Proton
pump inhibitor usage and the risk of mortality in
hemodialysis patients. Kidney Int Rep 2017; 3(2):
-84.
Meyer UA. Metabolic interactions of the protonpump
inhibitors lansoprazole, omeprazole and
pantoprazole with other drugs. European Journal
of Gastroenterology & Hepatology 1996; 8 (Suppl
: S21-5.
Kwok CS. Meta‐analysis: the effects of proton pump
inhibitors on cardiovascular events and mortality in
patients receiving clopidogrel. Aliment Pharmacol
Ther 2010; 31(8): 810-23.
Chen CB, Lin M, Eurich DT et al. Safety of concomitant
metformin and proton pump inhibitor use: a
population retrospective cohort study. Clin Ther
; 38(6): 1392-400.
Tvingsholm SA, Dehlendorff C, Østerlind K et al.
Proton pump inhibitor use and cancer mortality. Int
J Cancer 2018; 143(6): 1315-26.
Lee J, Youn K, Choi NK et al. A population-based casecontrol
study: proton pump inhibition and risk of hip
fracture by use of bisphosphonate. J Gastroenterol
; 48(9): 1016-22.
Chu MP, Hecht JR, Slamon D et al. Association of
proton pump inhibitors and capecitabine efficacy
in advanced gastroesophageal cancer: secondary
analysis of the TRIO-013/LOGiC randomized clinical
trial. JAMA Oncol 2017; 3(6): 767-73.
Mukherjee S, Jana T, Pan JJ. Adverse effects of proton
pump inhibitors on platelet count: a case report and
review of the literature. Case Rep Gastrointest Med
; 30: 4294805.
Madanick RD. Proton pump inhibitor side effects
and drug interactions: much ado about nothing?
Cleve Clin J Med 2011; 78(1): 39-49.
Lam JR, Schneider JL, Zhao W et al. Proton pump
inhibitor and histamine 2 receptor antagonist use
and vitamin B12 deficiency. JAMA 2013; 310(22):
-42.
Lam JR, Schneider JL, Quesenberry CP et al. Proton
pump inhibitor and Histamine-2 receptor antagonist
use and iron deficiency. Gastroenterology 2017;
(4): 821-9.57. Imai R, Higuchi T, Morimoto M, et al. Iron deficiency
anemia due to the long-term use of a proton Pump
inhibitor. Intern Med 2018; 57(6): 899-901.
Dado DN, Loesch EB, Jaganathan SP. A Case of Severe
Iron Deficiency Anemia Associated with Long-Term
Proton Pump Inhibitor Use. Curr Ther Res Clin Exp
; 84: 1-3.
Mabuchi S, Suzuki R, Sasaki M et al. Case report of
severe iron deficiency anemia caused by proton
pump inhibitor in an elderly patient. Geriatr Gerontol
Int 2017; 17(4): 662-3.
van Herwaarden N, Bos JM, Veldman B et al. Proton
pump inhibitors: not as safe as they seem. Ned
Tijdschr Geneeskd 2016; 160: D487.
Shikata T, Sasaki N, Ueda M et al. Use of proton pump
inhibitors is associated with anemia in cardiovascular
outpatients. Circ J 2015; 79(1): 193-200.
Hashimoto R, Matsuda T, Chonan A. Iron-deficiency
anemia caused by a proton pump inhibitor. Intern
Med 2014; 53(20): 2297-9.
Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils
and pitfalls of long-term effects of proton pump
inhibitors. Expert Rev Clin Pharmacol 2013; 6(4):
-51.
Heidelbaugh JJ. Proton pump inhibitors and risk of
vitamin and mineral deficiency: evidence and clinical
implications. Ther Adv Drug Saf 2013; 4(3): 125-33.
Sarzynski E, Puttarajappa C, Xie Y et al. Association
between proton pump inhibitor use and anemia: a
retrospective cohort study. Dig Dis Sci 2011; 56(8):
-53.
Ajmera AV, Shastri GS, Gajera MJ et al. Suboptimal
response to ferrous sulfate in iron-deficient patients
taking omeprazole. Am J Ther 2012; 19(3): 185-9.
Smith HS, Dhingra R, Ryckewaert L et al. Proton
pump inhibitors and pain. Pain Physician 2009; 12(6):
-23.
Mathieu N. Risk of long-term treatment with proton
pump inhibitors. Rev Prat 2008; 58(13): 1451-4.
Golubov J, Flanagan P, Adams P. Inhibition of iron
absorption by omeprazole in rat model. Dig Dis Sci
; 36(4): 405-8.
Khatib MA, Rahim O, Kania R et al. Iron deficiency
anemia: induced by long-term ingestion of
omeprazole. Dig Dis Sci 2002; 47(11): 2596-7.
Miller JW. Proton pump inhibitors, H2-receptor
antagonists, metformin, and Vitamin B-12 deficiency:
clinical implications. Adv Nutr 2018; 9(4): 511S-8S.
Gueta I, Halkin H, Markovits N et al. Proton pump
inhibitors and the risk for gastric cancer: possible
confounding by serum vitamin B 12. Gut 2017; 28.
Purchiaroni F, Galli G, Annibale B. Metformin plus
proton pump inhibitors therapy: the cobalamin
deficiency challenge. Eur Rev Med Pharmacol Sci
; 19(13): 2501-2.
Jung SB, Nagaraja V, Kapur A et al. Association
between vitamin B12 deficiency and long-term use
of acid-lowering agents: a systematic review and
meta-analysis. Intern Med J 2015; 45(4): 409-16.
Lam JR, Schneider JL, Zhao W et al. Proton pump
inhibitor and histamine 2 receptor antagonist use
and vitamin B12 deficiency. JAMA 2013; 310(22):
-42.
Zharkova A, Orlovsky V. Correlation between longterm
proton pump inhibitor use, homocysteine and
lipoproteins serum concentrations in patients with
comorbidity of ischemic heart disease and acid peptic
disease. Georgian Med News 2012; 213: 22-6.
Long AN, Atwell CL, Yoo W et al. Vitamin B (12)
deficiency associated with concomitant metformin
and proton pump inhibitor use. Diabetes Care 2012;
(12): e84.
Rozgony NR, Fang C, Kuczmarski MF et al. Vitamin
B(12) deficiency is linked with long-term use of
proton pump inhibitors in institutionalized older
adults: could a cyanocobalamin nasal spray be
beneficial? J Nutr Elder 2010; 29(1): 87-99.
Hirschowitz BI, Worthington J, Mohnen J. Vitamin
B12 deficiency in hypersecretors during long-term
acid suppression with proton pump inhibitors.
Aliment Pharmacol Ther 2008; 27(11): 1110-21.
Dharmarajan TS, Kanagala MR, Murakonda P et al.
Do acid-lowering agents affect vitamin B12 status in
older adults? J Am Med Dir Assoc 2008; 9(3): 162-7.
Valuck RJ, Ruscin JM. A case-control study on adverse
effects: H2 blocker or proton pump inhibitor use and
risk of vitamin B12 deficiency in older adults. J Clin
Epidemiol 2004; 57(4): 422-8.
Ruscin JM, Page RL, Valuck RJ. Vitamin B(12)
deficiency associated with histamine(2)-receptor
antagonists and a proton-pump inhibitor. Ann
Pharmacother 2002; 36(5): 812-6.
Schenk BE, Kuipers EJ, Klinkenberg-Knol EC et al.
Atrophic gastritis during long-term omeprazole
therapy affects serum vitamin B12 levels. Aliment
Pharmacol Ther 1999; 13(10): 1343-6.
Sagar M, Janczewska I, Ljungdahl A et al. Effect of
CYP2C19 polymorphism on serum levels of vitamin
B12 in patients on long-term omeprazole treatment.
Aliment Pharmacol Ther 1999; 13(4): 453-8.
Bellou A, Aimone-Gastin I, De Korwin JD et al.
Cobalamin deficiency with megaloblastic anaemia
in one patient under long-term omeprazole therapy.
J Intern Med 1996; 240(3): 161-4.
Saltzman JR, Kemp JA, Golner BB et al. Effect of
hypochlorhydria due to omeprazole treatment or
atrophic gastritis on protein-bound vitamin B12
absorption. J Am Coll Nutr 1994; 13(6): 584-91.
Marcuard SP, Albernaz L, Khazanie PG. Omeprazole
therapy causes malabsorption of cyanocobalamin
(vitamin B12). Ann Intern Med 1994; 120(3): 211-5.
Liang JF, Chen YT, Fuh JL et al. Proton pump inhibitorrelated headaches: a nationwide population-based
case-crossover study in Taiwan. Cephalalgia 2015;
(3): 203-10.
Wu JC, Lai LH, Chow DK et al. Concomitant irritable
bowel syndrome is associated with failure of stepdown
on-demand proton pump inhibitor treatment
in patients with gastro-esophageal reflux disease.
Neurogastroenterol Motil 2011; 23(2): 155-60.
Shah R, Richardson P, Yu H et al. Gastric acid
suppression is associated with an increased risk of
adverse outcomes in inflammatory bowel disease.
Digestion 2017; 95(3): 188-93.
Wang YF, Chen YT, Luo JC et al. Proton-pump inhibitor
use and the risk of first-time ischemic stroke in the
general population: a nationwide population-based
study. Am J Gastroenterol 2017; 112(7): 1084-93.
Yang YX, Lewis JD, Epstein S et al. Long-term proton
pump inhibitor therapy and risk of hip fracture. JAMA
; 296(24): 2947-53.
Ding J, Heller DA, Ahern FM et al. The relationship
between proton pump inhibitor adherence and
fracture risk in the elderly. Calcif Tissue Int 2014;
(6): 597-607.
Freedberg DE, Haynes K, Denburg MR et al. Use of
proton pump inhibitors is associated with fractures in
young adults: a population-based study. Osteoporos
Int 2015; 26(10): 2501-7.
Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of
fractures with acid-suppressing medication. Bone
; 48(4): 768-76.
McGowan B, Bennett K, Barry M. Prescribing of
anti-osteoporotic therapies following the use
of proton pump inhibitors in general practice.
Pharmacoepidemiol Drug Saf 2010; 19(7): 763-9.
Corley DA, Kubo A, Zhao W et al. Proton pump
inhibitors and histamine-2 receptor antagonists are
associated with hip fractures among at-risk patients.
Gastroenterology 2010; 139(1): 93-101.
Gomm W, von Holt K, Thomé F et al. Association
of proton pump inhibitors with risk of dementia:
a pharmacoepidemiological claims data analysis.
JAMA Neurol 2016; 73(4): 410-6.
Ho SW, Teng YH, Yang SF et al. Association of Proton
Pump Inhibitors Usage with Risk of Pneumonia in
Dementia Patients. J Am Geriatr Soc 2017; 65(7):
-7.
Drug Safety and Availability – FDA. Drug Safety
Communication: Low magnesium levels can be
associated with long-term use of Proton Pump
Inhibitor drugs (PPIs). Available on: www.fda.gov.
Accessed on: August 23, 2018.
Hess MW, Hoenderop JG, Bindels RJ et al. Systematic
review: Hypomagnesaemia induced by proton pump
inhibition. Aliment Pharmacol Ther 2012; 36: 405-13.
Kieboom BC, Kiefte-de Jong JC, Eijgelsheim M et al.
Proton pump inhibitors and hypomagnesemia in
the general population: A population-based cohort
study. Am J Kidney Dis 2015; 66: 775-82.
Bai JP, Hausman E, Lionberger R et al. Modeling and
simulation of the effect of proton pump inhibitors
on magnesium homeostasis 1. Oral absorption of
magnesium. Mol Pharm 2012; 9: 3495-505.
Nakashima A, Ohkido I, Yokoyama K et al. Proton
pump inhibitor use and magnesium concentrations
in hemodialysis patients: A cross-sectional study.
PLoS One 2015; 10: e014365.
Hoorn EJ, van der Hoek J, de Man RA et al. A case series
of proton pump inhibitor-induced hypomagnesemia.
Am J Kidney Dis 2010; 56: 112-6.
Kieboom BC, Kiefte-de Jong JC, Eijgelsheim M et al.
Proton pump inhibitors and hypomagnesemia in
the general population: a population-based cohort
study. Am J Kidney Dis 2015; 66(5): 775-82.
Zipursky J, Macdonald EM, Hollands S et al.
Proton pump inhibitors and hospitalization with
hypomagnesemia: a population-based case-control
study. PLoS Med 2014; 11(9): e1001736.
Chu MP, Hecht JR, Slamon D et al. Association of
proton pump inhibitors and capecitabine efficacy
in advanced gastroesophageal cancer: secondary
analysis of the TRIO-013/LOGiC randomized clinical
trial. JAMA Oncol 2017; 3(6): 767-73.
Murphy SJ, Dickey W, Hughes D et al. Surveillance for
Barrett’s oesophagus: results from a programme in
Northern Ireland. Eur J Gastroenterol Hepatol 2005;
(10): 1029-35.
Jankowski J, Sharma P. Approaches to Barrett’s
oesophagus treatment-the role of proton pump
inhibitors and other interventions. Aliment
Pharmacol Ther 2004; 19 Suppl 1: 54-9.
Poulsen AH, Christensen S, McLaughlin JK et al.
Proton pump inhibitors and risk of gastric cancer:
a population-based cohort study. Br J Cancer 2009;
(9): 1503-7.
Tran KT, McMenamin ÚC, Hicks B et al. Proton pump
inhibitor and histamine-2 receptor antagonist use
and risk of liver cancer in two population-based
studies. Aliment Pharmacol Ther 2018; 48(1): 55-64.
Van Soest EM, van Rossum LG, Dieleman JP et al.
Proton pump inhibitors and the risk of colorectal
cancer. Am J Gastroenterol 2008; 103(4): 966-73.
Peng YC, Lin CL, Hsu WY et al. Association between
cholangiocarcinoma and proton pump inhibitors
use: a nested case-control study. Front Pharmacol.
; 9: 718.
Cheung KS, Chan EW, Wong AYS et al. Long-term
proton pump inhibitors and risk of gastric cancer
development after treatment for Helicobacter pylori:
a population-based study. Gut 2018; 67(1): 28-35.
Waldum HL. Editorial: proton pumps inhibitors (PPIs)
and primary liver cancer. Aliment Pharmacol Ther.
; 48(3): 380-1.117. Chubak J, Boudreau DM, Rulyak SJ et al. Colorectal
cancer risk in relation to use of acid suppressive
medications. Pharmacoepidemiol Drug Saf 2009;
(7): 540-4.
Chien LN, Huang YJ, Shao YH et al. Proton pump
inhibitors and risk of periampullary cancers--A nested
case-control study. Int J Cancer 2016; 138(6): 1401-9.
Tamim H, Duranceau A, Chen LQ et al. Association
between use of acid-suppressive drugs and risk of
gastric cancer. A nested case-control study. Drug Saf
; 31(8): 675-84.
Jackson MA, Goodrich JK, Maxan ME et al. Proton
pump inhibitors alter the composition of the gut
microbiota. Gut 2016; 65(5): 749-56.
Alsalahi O, Dobrian AD. Proton Pump Inhibitors:
The Culprit for Barrett’s Esophagus? Front Oncol
; 4: 373.
Nomura M, Tashiro N, Watanabe T et al. Association
of symptoms of gastroesophageal reflux with
metabolic syndrome parameters in patients with
endocrine disease. Gastroenterol 2014: 863206.
Proton Pump Inhibitors: U.S. Food and drug
administration-approved indications and dosages for
use in adults. Available from: https://www.cms.gov/
Medicare-Medicaid-Coordination/Fraud-Prevention/
Medicaid-Integrity-Education/Pharmacy-Education-
Materials/Downloads/ppi-adult-dosingchart.pdf.
Accessed on: August 10, 2018.
Scholten T. Long-term management of gastroesophageal
reflux disease with pantoprazole. Ther Clin
Risk Manag 2007; 3(2): 231-43.
Spechler SJ, Goyal RK. Barrett’s esophagus. N Engl
J Med 1986; 315(6): 362-71.
Vakil N, Talley NJ, Stolte M et al. Patterns of gastritis
and the effect of eradicating Helicobacter pylori on
gastro-oesophageal reflux disease in Western patients
with non-ulcer dyspepsia. Aliment Pharmacol Ther
; 24(1): 55-63.
Suleiman K, Limas K, Hartmut H et al. Pantoprazole
mg on demand is effective in the long-term
management of patients with mild gastrooesophageal
reflux disease. European Journal of
Gastroenterology & Hepatology 2005; 7(9): 935-41.
Dabrowski A, Štabuc B, Lazebnik L. Meta-analysis
of the efficacy and safety of pantoprazole in the
treatment and symptom relief of patients with
gastroesophageal reflux disease - PAN-STAR. Prz
Gastroenterol. 2018; 13(1): 6-15.
Cicala M, Emerenziani S, Guarino MP et al. Proton
pump inhibitor resistance, the real challenge
in gastro-esophageal reflux disease. World J
Gastroenterol 2013; 19(39): 6529-35.
Mohamed AH, Hunt RH. The rationale of acid
suppression in the treatment of acid-related disease.
Aliment Pharmacol Ther 1994; 8 Suppl 1: 3-10.
Bardhan KD. Duodenal ulcer and gastroesophageal
reflux disease today: long-term therapy-a sideways
glance. J Biol Med 1996; 69(3): 211-24.
Padhy BM, Bhadauria HS, Gupta YK. Attitude and
Knowledge of Indian Emergency Care Residents
towards Use of Proton Pump Inhibitors. International
Scholarly Research 2014: 6.
Boath EH, Blenkinsopp A.The rise and rise of proton
pump inhibitor drugs: patients’ perspectives. Soc Sci
Med 1997; 45(10): 1571-9.
Scarpignato C, Gatta L, Zullo A et al. Effective and
safe proton pump inhibitor therapy in acid-related
diseases - A position paper addressing benefits and
potential harms of acid suppression. BMC Med 2016;
-14(1): 179.
Malavade P, Hiremath S. Proton pump inhibitors:
More indigestion than relief? Indian Journal of
Nephrology 2017; 27(4): 249-57.
Wilkinson SP, Biddlestone L, Gore S et al. Regression
of columnar-lined (Barrett’s) oesophagus with
omeprazole 40 mg daily: results of 5 years of
continuous therapy. Aliment Pharmacol Ther 1999;
(9): 1205-9.
Wani S, Sampliner RE, Weston AP et al. Lack of
predictors of normalization of oesophageal acid
exposure in Barrett’s oesophagus. Aliment Pharmacol
Ther. 2005; 22(7): 627-33.
Singh A, Cresci GA, Kirby DF. Proton Pump Inhibitors:
Risks and Rewards and Emerging Consequences to
the Gut Microbiome. Nutr Clin Pract 2018; 33(5):
-24.
Malavade P, Hiremath S. Proton pump inhibitors:
More indigestion than relief? Indian J Nephrol 2017;
: 249-57.
Andersen AB, Erichsen R, Farkas DK et al. Prenatal
exposure to acid-suppressive drugs and the risk of
childhood asthma: a population-based Danish cohort
study. Aliment Pharmacol Ther 2012;35(10): 1190-8.
Roulet L, Vernaz N, Giostra E et al. Adverse effects
of proton pump inhibitors: should we worry about
long-term exposure? Rev Med Interne 2012; 33(8):
-45.
Naito Y, Kashiwagi K, Takagi T et al. Intestinal Dysbiosis
Secondary to Proton-Pump Inhibitor Use. Digestion
; 97(2): 195-204.
Laine L, Ahnen D, McClain C et al. Potential gastrointestinal
effects of long-term acid suppression with
proton pump inhibitors. Aliment Pharmacol Ther
; 14(6): 651-68.
Bavishi C, Dupont HL. Systematic review: The uses of
proton pump inhibitors and increased susceptibility
to enteric infection. Aliment. Pharmacol Ther 2011;
(11-12): 1269-81.
Cicala M, Emerenziani S, Guarino MP et al. Proton
pumps inhibitor resistance, the real challenge
in gastro-esophageal reflux disease. World J
Gastroenterol 2013; 19(39): 6529-35.146. Savarino E, Marabotto E, Zentilin P et al. A safety
review of proton pump inhibitors to treat acid-related
digestive diseases. Expert Opin Drug Saf 2018; 23:
-10.
Sheen E, Triadafilopoulos G. Adverse effects of longterm
proton pump inhibitor therapy. Dig Dis Sci
; 56(4): 931-50.
Ali T, Roberts DN, Tierney WM. Long-term safety
concerns with proton pump inhibitors. Am J Med
; 122(10): 896-90.
Ament PW, Dicola DB, James ME. Reducing adverse
effects of proton pump inhibitors. Am Fam Physician
; 86(1): 66-70.
Cicala M, Emerenziani S, Guarino MP et al. M Proton
pump inhibitor resistance, the real challenge in gastroesophageal
reflux disease. World J Gastroenterol
; 19(39): 6529-35.
Carlo Calabrese, Anna Fabbri, Giulio Di Febo. Longterm
management of GERD in the elderly with
pantoprazole. Clin Interv Aging 200; 2(1): 85–92.
Zhong Li, Cong Wu, Ling Li et al. Effect of longterm
proton pump inhibitor administration on
gastric mucosal atrophy: A meta-analysis. Saudi J
Gastroenterol 2017; 23(4): 222-228.
Refbacks
- There are currently no refbacks.
Copyright (c) 2018 Journal of Advanced Research in Medicine (P-ISSN:2394-7047 & E-ISSN:2349-7181)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.